ClinicalTrials.gg
TerminatedNCT04464564Updated May 30, 2025Results posted

Study to Assess the Efficacy, Safety, and Tolerability of AVP-786 for the Treatment of Agitation in Patients With Dementia of the Alzheimer's Type

A Phase 3 interventional study of AVP-786 and Placebo in Agitation in Patients With Dementia of the Alzheimer's Type, sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc.. Terminated at 106 sites in 13 countries. Open to participants aged 50 Years to 90 Years. Per ClinicalTrials.gov, last updated 2025-05-30.

Primary conditionPsychomotor Agitation(the registry's first term)UnverifiedIs this wrong?The registry often attaches Psychomotor Agitation to studies about something else, and this study's title and listed conditions do not name it. No better condition is named, so the registry's term is kept.

Sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc. (part of Otsuka Holdings Co., Ltd.) · Phase 3, Interventional, and Treatment

Why this study was terminated
The AVP-786 program was discontinued, the recruitment was stopped and all participants are no longer being examined or receiving intervention.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
241
Allocation
Randomized
Ages
50 Years to 90 Years
Sex
All
01

Study summary

This study was conducted to evaluate the efficacy, safety, and tolerability of AVP-786 (deudextromethorphan hydrobromide [d6-DM]/quinidine sulfate [Q]) compared to placebo for the treatment of agitation in participants with dementia of the Alzheimer's type.

Read the detailed description

Eligible participants for this study had a diagnosis of probable Alzheimer's disease (AD) and had clinically significant, moderate/severe agitation secondary to AD.

This was multicenter, randomized, double-blind, placebo-controlled study, consisting of 12 weeks of treatment. Screening occurred within 4 weeks prior to randomization. Following screening procedures for assessment of inclusion and exclusion criteria, eligible participants were randomized into the study.

241 participants were enrolled into the study.

Study medication was administered orally twice daily from Day 1 through Day 85.

02

Conditions studied

  • Agitation in Patients With Dementia of the Alzheimer's Type

Browse trials for

Keywords

  • Agitation
  • Dementia of the Alzheimer's type
  • Alzheimer's disease
  • AVP-786
  • Deudextromethorphan hydrobromide
  • Quinidine sulfate
03

In context

Psychomotor Agitation Unverified

231 studies on the registry are indexed under Psychomotor Agitation; 28 are open to participants now.

This study's enrollment of 241 is above the median of 100 across 188 interventional studies indexed under Psychomotor Agitation.

Browse Psychomotor Agitation studies →

Lead sponsor

Otsuka Pharmaceutical Development & Commercialization, Inc. is the lead sponsor of 297 studies on the registry; 19 are open to participants now.

Of its 106 completed or terminated interventional studies of FDA-regulated products, 71 (67%) have results posted.

Compared within Psychomotor Agitation, the registry's first condition term, which may not be this study's main condition. Counted across the registry records on this site, refreshed daily. How we classify →

04

Who can participate

Ages eligible
50 Years to 90 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants with a diagnosis of probable Alzheimer's disease according to the 2011 Neuropsychiatric Inventory Agitation/Aggression (NPI-AA) working groups criteria
  • Participants with , moderate-to-severe agitation for at least 2 weeks prior to Screening that interferes with daily routine per the Investigator's judgment
  • Participants who require pharmacotherapy for the treatment of agitation per the Investigator's judgment after an evaluation of reversible factors and a course of nonpharmacological interventions
  • Diagnosis of agitation must meet the International Psychogeriatric Association (IPA) provisional definition of agitation.
  • Participants meeting an additional predetermined blinded eligibility criterion, which will remain blinded to the clinical study site Investigators and staff
  • Participants with a reliable caregiver who is able and willing to comply with all study procedures, including adherence to administering study drug and not administering any prohibited medications during the course of the study, and who spends a minimum of 2 hours per day for 4 days per week with the participant

Exclusion criteria

Exclusion Criteria:

  • Participants with dementia predominantly of the non-Alzheimer's type (e.g., vascular dementia, frontotemporal dementia, Parkinson's disease, substance-induced dementia)
  • Participants with symptoms of agitation that are not secondary to Alzheimer's dementia (e.g., secondary to pain, other psychiatric disorder, or delirium)
  • Participants with co-existent or unstable systemic diseases that could confound the interpretation of the safety results of the study (e.g., [except skin basal-cell carcinoma], poorly controlled diabetes, poorly controlled hypertension, unstable pulmonary, renal or hepatic disease, unstable ischemic cardiac disease, dilated cardiomyopathy, or unstable valvular heart disease)
  • Participants with myasthenia gravis
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
241 participants (actual)

Study arms

  • Placebo comparator
    Placebo

    Participants who were enrolled in 1-week double-blind placebo lead-in Period A, were then randomized to receive AVP-786 matching placebo capsules, twice a day, for 11 weeks in Period B.

    Drug: Placebo

  • Experimental
    AVP-786-18

    Participants who were enrolled in 1-week double-blind placebo lead-in Period A, were then randomized to receive AVP-786-18 (d6-DM 18 milligrams (mg)/Q 4.9 mg) capsules, twice a day, for 11 weeks in Period B.

    Drug: AVP-786

  • Experimental
    AVP-786-42.63

    Participants who were enrolled in 1-week double-blind placebo lead-in Period A, were then randomized to receive AVP-786-42.63 (d6-DM 42.63 mg/Q 4.9 mg) capsules, twice a day, for 11 weeks in Period B.

    Drug: AVP-786

Interventions

06

What researchers measure

Primary outcomes

  1. Change From the End of Period A (Week 1) to Week 10 in the Cohen-Mansfield Agitation Inventory (CMAI) Composite Score

    The CMAI is used to assess the frequency of manifestations of agitated behaviors in elderly persons. It consists of 29 agitated behaviors that are further categorized into distinct agitation syndromes, also known as CMAI factors of agitation. These distinct agitation syndromes include aggressive behavior, physically nonaggressive behavior, and verbally agitated behavior. Each of the 29 items is rated on a 7-point scale of frequency (1 = never, 2 = less than once a week but still occurring, 3 = once or twice a week, 4 = several times a week, 5 = once or twice a day, 6 = several times a day, 7 = several times an hour). The ratings are based on the 2 weeks preceding assessment of the CMAI. Higher scores indicate higher frequency of agitated behaviours while lower scores indicate lower frequency of agitated behaviours.

    Time frame: Week 1 to Week 10

  2. Number of Participants With Treatment Emergent Adverse Events (TEAE) and Serious TEAE

    An adverse event (AE) is any untoward medical occurrence or unintended change (eg, physical, psychological, or behavioral), including inter-current illness, that does not necessarily have a causal relationship with the study treatment. A serious adverse event (SAE) is any AE occurring at any dose that results in death, life-threatening experience, persistent or significant disability/incapacity, in-patient hospitalization or prolongation of hospitalization or congenital anomaly/birth defect. TEAEs are all AEs (including serious and non-serious) which started after start of double-blind study drug treatment; or if the event was continuous from baseline and was worsening, serious, study drug related, or resulted in death, discontinuation, interruption or reduction of study therapy.

    Time frame: From randomization (Week 2) up to 30 days after last dose of study drug (Up to Week 16)

Secondary outcomes

  1. Change From the End of Period A (Week 1) to Week 10 in the Clinical Global Impression of Severity of Illness (CGIS) Score, as Related to Agitation

    The CGIS is an observer-rated scale that measures illness severity. The CGIS-Agitation is a 7-point (1-7) scale (1 = normal, not at all ill; 7 = among the most extremely ill patients) and assesses severity of agitation in this study. Higher scores indicate severe agitation while the lower scores indicate little or no agitation.

    Time frame: Week 1 to Week 10

07

Results

Posted May 30, 2025
Limitations and caveats
The study was prematurely terminated due to discontinuation of development of the AVP-786 compound.

Participant flow

Participants took part in the study at clinical sites in the North America, Latin America and Europe from 11 September 2020 to 28 June 2024.

Period A (Placebo lead-in)
Participant flow — Period A (Placebo lead-in)
MilestoneAll EnrolledPlaceboAVP-786-18AVP-786-42.63
Started241000
Completed236000
Not completed5000
Withdrew: Other5000
Period B (Randomization Period)
Participant flow — Period B (Randomization Period)
MilestoneAll EnrolledPlaceboAVP-786-18AVP-786-42.63
Started0768377
Safety population0768377
Completed0566152
Not completed0202225
Withdrew: Adverse event0128
Withdrew: Lack of efficacy0100
Withdrew: Lost to follow-up0001
Withdrew: Study subject withdrawal by parent or guardian0335
Withdrew: Study terminated by sponsor010107
Withdrew: Withdrawal by subject0241
Withdrew: Reason not specified0333

Outcome measures

PrimaryChange From the End of Period A (Week 1) to Week 10 in the Cohen-Mansfield Agitation Inventory (CMAI) Composite Score

The CMAI is used to assess the frequency of manifestations of agitated behaviors in elderly persons. It consists of 29 agitated behaviors that are further categorized into distinct agitation syndromes, also known as CMAI factors of agitation. These distinct agitation syndromes include aggressive behavior, physically nonaggressive behavior, and verbally agitated behavior. Each of the 29 items is rated on a 7-point scale of frequency (1 = never, 2 = less than once a week but still occurring, 3 = once or twice a week, 4 = several times a week, 5 = once or twice a day, 6 = several times a day, 7 = several times an hour). The ratings are based on the 2 weeks preceding assessment of the CMAI. Higher scores indicate higher frequency of agitated behaviours while lower scores indicate lower frequency of agitated behaviours.

Time frame:
Week 1 to Week 10

No measurements were reported for this outcome.

PrimaryNumber of Participants With Treatment Emergent Adverse Events (TEAE) and Serious TEAE

An adverse event (AE) is any untoward medical occurrence or unintended change (eg, physical, psychological, or behavioral), including inter-current illness, that does not necessarily have a causal relationship with the study treatment. A serious adverse event (SAE) is any AE occurring at any dose that results in death, life-threatening experience, persistent or significant disability/incapacity, in-patient hospitalization or prolongation of hospitalization or congenital anomaly/birth defect. TEAEs are all AEs (including serious and non-serious) which started after start of double-blind study drug treatment; or if the event was continuous from baseline and was worsening, serious, study drug related, or resulted in death, discontinuation, interruption or reduction of study therapy.

Time frame:
From randomization (Week 2) up to 30 days after last dose of study drug (Up to Week 16)
Reported as:
Count of participants · Participants
Number of Participants With Treatment Emergent Adverse Events (TEAE) and Serious TEAE
ParticipantsPlaceboAVP-786-18AVP-786-42.63
TEAEs253834
Serious TEAEs455
SecondaryChange From the End of Period A (Week 1) to Week 10 in the Clinical Global Impression of Severity of Illness (CGIS) Score, as Related to Agitation

The CGIS is an observer-rated scale that measures illness severity. The CGIS-Agitation is a 7-point (1-7) scale (1 = normal, not at all ill; 7 = among the most extremely ill patients) and assesses severity of agitation in this study. Higher scores indicate severe agitation while the lower scores indicate little or no agitation.

Time frame:
Week 1 to Week 10

No measurements were reported for this outcome.

Adverse events

Collected over From randomization (Week 2) up to 30 days after last dose of study drug (Up to Week 16). Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo1/76 (1.3%)4/76 (5.3%)25/76 (32.9%)
AVP-786-180/83 (0%)5/83 (6%)38/83 (45.8%)
AVP-786-42.631/77 (1.3%)5/77 (6.5%)32/77 (41.6%)
Most frequent serious events
Showing 10 of 19
Most frequent serious events
EventPlaceboAVP-786-18AVP-786-42.63
DeathGeneral disorders1/760/830/77
PneumoniaInfections and infestations1/761/830/77
Upper respiratory tract infectionInfections and infestations1/760/830/77
Urinary tract infectionInfections and infestations1/760/830/77
Accidental exposure to productInjury, poisoning and procedural complications1/760/830/77
DeliriumPsychiatric disorders1/760/830/77
Acute myocardial infarctionCardiac disorders0/760/831/77
Upper gastrointestinal haemorrhageGastrointestinal disorders0/760/831/77
Hip fractureInjury, poisoning and procedural complications0/760/831/77
DizzinessNervous system disorders0/761/831/77
Most frequent other events
Showing 10 of 115
Most frequent other events
EventPlaceboAVP-786-18AVP-786-42.63
FallInjury, poisoning and procedural complications3/767/839/77
DizzinessNervous system disorders4/763/835/77
Urinary tract infectionInfections and infestations1/765/834/77
SomnolenceNervous system disorders0/760/834/77
FatigueGeneral disorders1/764/831/77
Gait disturbanceGeneral disorders0/761/833/77
HypertensionVascular disorders0/763/830/77
Asymptomatic bacteriuriaInfections and infestations0/761/832/77
COVID-19Infections and infestations1/760/832/77
InfluenzaInfections and infestations0/760/832/77

Baseline characteristics

Randomized population included all participants who were randomized in the double-blind period B of the study.

Age, Continuous
Age, Continuous(years)PlaceboAVP-786-18AVP-786-42.63Total
Mean75.2 ± 7.2776.4 ± 7.5076.5 ± 7.4376.0 ± 7.40
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboAVP-786-18AVP-786-42.63Total
Female424955146
Male34342290
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)PlaceboAVP-786-18AVP-786-42.63Total
Race — White606257179
Race — Black or African American83415
Race — Asian0101
Race — American Indian or Alaska Native59822
Race — Other38819
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)PlaceboAVP-786-18AVP-786-42.63Total
Ethnicity — Hispanic or Latino394648133
Ethnicity — Not Hispanic or Latino353629100
Ethnicity — Other2103
08

Study locations

106 sites
  • Clinical Research Site #840-020
    Phoenix, Arizona 85004, United States
  • Clinical Research Site #840-047
    Anaheim, California 92805, United States
  • Clinical Research Site #840-090
    Costa Mesa, California 92626, United States
  • Clinical Research Site #840-059
    Lafayette, California 94549, United States
  • Clinical Research Site #840-048
    Lomita, California 90717, United States
  • Clinical Research Site #840-095
    Long Beach, California 90807, United States
  • Clinical Research Site #840-004
    Los Angeles, California 90024, United States
  • Clinical Research Site #840-006
    Panorama City, California 91402, United States
  • Clinical Research Site
    San Diego, California 92128, United States
  • Clinical Research Site #840-070
    Apopka, Florida 32703, United States
  • Clinical Research Site #840-055
    Bradenton, Florida 34205, United States
  • Clinical Research Site #840-096
    Cape Coral, Florida 33904, United States
  • Clinical Research Site #840-077
    Clermont, Florida 34771, United States
  • Clinical Research Site #840-066
    Coral Springs, Florida 33067, United States
  • Clinical Research Site #840-039
    Hallandale Beach, Florida 33009, United States
  • Clinical Research Site #840-089
    Kissimmee, Florida 34741, United States
  • Clinical Research Site #840-034
    Lady Lake, Florida 32159, United States
  • Clinical Research Site #840-037
    Miami, Florida 33122, United States
  • Clinical Research Site #840-092
    Miami, Florida 33125, United States
  • Clinical Research Site #840-041
    Miami, Florida 33126, United States
  • Clinical Research Site #840-007
    Miami, Florida 33145, United States
  • Clinical Research Site #840-103
    Miami, Florida 33175, United States
  • Clinical Research Site #840-042
    Miami, Florida 33176, United States
  • Clinical Research Site #840-051
    Naples, Florida 34105, United States
  • Clinical Research Site #840-087
    Orlando, Florida 32807, United States
  • Clinical Research Site 840-028
    Pensacola, Florida 32502, United States
  • Clinical Research Site # 840-105
    Tampa, Florida 33614, United States
  • Clinical Research Site #840-104
    Tampa, Florida 33614, United States
  • Clinical Research Site #840-049
    West Palm Beach, Florida 33407, United States
  • Clinical Research Site #840-036
    Winter Park, Florida 32789, United States
  • Clinical Research Site #840-065
    Atlanta, Georgia 30318, United States
  • Clinical Research Site #840-030
    Chicago, Illinois 60637, United States
  • Clinical Research Site #840-073
    Boston, Massachusetts 02131, United States
  • Clinical Research Site #840-014
    Bloomfield Township, Michigan 48302, United States
  • Clinical Research Site #840-022
    Detroit, Michigan 48201, United States
  • Clinical Research Site #840-024
    O'Fallon, Missouri 63368, United States
  • Clinical Research Site #840-031
    Buffalo, New York 14030, United States
  • Clinical Research Site #840-021
    Manhasset, New York 11030, United States
  • Clinical Research Site #840-058
    New Hyde Park, New York 11040, United States
  • Clinical Research Site #840-035
    Cypress, Texas 77429, United States
  • Clinical Research Site #840-053
    Dallas, Texas 75206, United States
  • Clinical Research Site #840-093
    El Paso, Texas 79902, United States
  • Clinical Research Site #840-072
    Houston, Texas 77063, United States
  • Clinical Research Site #840-057
    Houston, Texas 77077, United States
  • Clinical Research Site #840-086
    Mesquite, Texas 75149, United States
  • Clinical Research Site #840-044
    Fairfax, Virginia 22031, United States
  • Clinical Research Site #056-005
    Alken, Limburg 3570, Belgium
  • Clinical Research Site #056-004
    Brussel, 1070, Belgium
  • Clinical Research Site #056-003
    Leuven, 3000, Belgium
  • Clinical Research Site # 056-002
    Liège, 4000, Belgium
  • Clinical Research Site #124-003
    Kelowna, British Columbia V1Y 1Z9, Canada
  • Clinical Research Site #124-008
    Quebec City, Quebec G3K 2P8, Canada
  • Clinical Research Site #152-007
    Viña Del Mar, Region Metropolitana De Santiago 2451029, Chile
  • Clinical Research Site #152-002
    Antofagasta, 1270244, Chile
  • Clinical Research Site #152-005
    Independencia, 8380456, Chile
  • Clinical Research Site #152-001
    Santiago de Chile, 7500710, Chile
  • Clinical Research Site #152-006
    Santiago de Chile, 9120000, Chile
  • Clinical Research Site #152-003
    Santiago, 7560356, Chile
  • Clinical Research Site #170-003
    Bogota, Columbia 111166, Colombia
  • Clinical Research Site #170-002
    Pereira, Columbia 1111, Colombia
  • Clinical Research Site #170-007
    Florida Blanca, Santander 111511, Colombia
  • Clinical Research Site #170-006
    Bello, 051050, Colombia
  • Clinical Research Site #170-001
    Bogota, 110231, Colombia
  • Clinical Research Site #170-004
    Bogotá, 110231, Colombia
  • Clinical Research Site #191-008
    Pula, Istarska Županija 52000, Croatia
  • Clinical Research Site# 191-006
    Rijeka, 51000, Croatia
  • Clinical Research Site# 191-001
    Zagreb, 10000, Croatia
  • Clinical Research Site #191-003
    Zagreb, 1000, Croatia
  • Clinical Research Site #191-005
    Zagreb, HR 10000, Croatia
  • Clinical Research Site #191-002
    Zagreb, HR-10090, Croatia
  • Clinical Research Site #348-002
    Gyöngyös, Heves 3200, Hungary
  • Clinical Research Site #384-001
    Budapest, 1036, Hungary
  • Clinical Research Site #384-003
    Budapest, 1036, Hungary
  • Clinical Research Site #348-004
    Zalaegerszeg, 8900, Hungary
  • Clinical Research Site #372-002
    Cork, T12 WE28, Ireland
  • Clinical Research Site #372-003
    Cork, T12 XH60, Ireland
  • Clinical Research Site #372-004
    Dublin, 24, Ireland
  • Clinical Research Site #372-001
    Dublin, D08 E191, Ireland
  • Clinical Research Site #484-008
    Merida, 97070, Mexico
  • Clinical Research Site # 484-004
    Mexico City, 7000, Mexico
  • Clinical Research Site #484-006
    Monterrey, 64310, Mexico
  • Clinical Research Site #484-005
    Monterrey, 64460, Mexico
  • Clinical Research Site # 484-003
    Monterrey, 64710, Mexico
  • Clinical Research Site #484-010
    Saltillo, 25020, Mexico
  • Clinical Research Site # 484-002
    Sinaloa, 80020, Mexico
  • Clinical Research Site #484-009
    Tlalnepantla, 54055, Mexico
  • Clinical Trial Site #528-001
    Amsterdam, 1081GN, Netherlands
  • Clinical Research Site #703-009
    Dubnica Nad Váhom, Bratislavský Kraj 01851, Slovakia
  • Clinical Research Site #703-104
    Rimavska Sobota, Sobota 97901, Slovakia
  • Clinical Research Site #703-006
    Banská Bystrica, 97404, Slovakia
  • Clinical Research Site #703-002
    Bardejov, 08501, Slovakia
  • Clinical Research Site #703-005
    Košice, 04001, Slovakia
  • Clinical Research Site #703-003
    Trencin, 91108, Slovakia
  • Clinical Research Site #703-001
    Vranov Nad Topľou, 09301, Slovakia
  • Clinical Research Site #705-006
    Murska Sobota, Brezovica 9000, Slovenia
  • Clinical Research Site #705-004
    Begunje na Gorenjskem, 4275, Slovenia
  • Clinical Research Site #705-003
    Ljubljana, 1000, Slovenia
  • Clinical Research Site #705-002
    Ljubljana, 1260, Slovenia
  • Clinical Research Site #705-005
    Maribor, 2000, Slovenia
  • Clinical Research Site #705-001
    Nova Gorica, 52905000, Slovenia

Showing the first 100 of 106 sites across 13 countries. Choose a country and city above to see the rest.

09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Anonymized Individual participant data (IPD) that underlie the results of this study will be shared with researchers to achieve aims pre-specified in a methodologically sound research proposal. Small studies with less than 25 participants are excluded from data sharing.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: Data will be available after marketing approval in global markets or beginning 1-3 years following article publication. There is no end date to the availability of the data.

Access criteria: Otsuka will share data on the Vivli data sharing platform which can be found here: https://vivli.org/ourmember/Otsuka/

Data sharing details ↗ · clinical-trials.otsuka.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Sep 2020 to primary completion in Jun 2024, 45 months.

Results were first posted in May 2025, 11 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 6, 2020
First posted
Jul 9, 2020
StartActual
Sep 11, 2020
Primary completionActual
Jun 28, 2024
CompletionActual
Jun 28, 2024
Results first posted
May 30, 2025
Last update
May 30, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 30, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04464564
Responsible party
Sponsor
First posted
Jul 9, 2020
Start date
Sep 11, 2020
Primary completion
Jun 28, 2024
Completion
Jun 28, 2024
Results posted
May 30, 2025
Last update
May 30, 2025

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in May 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Deudextromethorphan · Quinidine

Start the discussion